Maintenance therapy in gastro-oesophageal reflux disease

Drugs

Volumn 65, Issue SUPPL. 1, 2005, Pages 59-66

  Bixquert, Miguel ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR;

ADENOCARCINOMA; ANTIREFLUX OPERATION; CANCER PREVENTION; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPLASIA; ENDOSCOPIC THERAPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; HYPERGASTRINEMIA; INFECTION RISK; INTESTINE METAPLASIA; LONG TERM CARE; MAINTENANCE THERAPY; MEDICAL INFORMATION; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; STOMACH ADENOCARCINOMA; STOMACH CARCINOID; STOMACH FUNDOPLICATION; TACHYPHYLAXIS; TEAMWORK; VAGOTOMY; WOUND HEALING;

HELICOBACTER PYLORI;

EID: 30344485682     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565001-00009     Document Type: Review

References (35)

1. Eissele R, Arnold R. Long-term management of GERD. In: Misiewicz JJ, editor. Management Issues in Gastroesophageal Reflux Disease. London: Life Science Communications, 1999: 24-33
2. Richter JE. Gastroesophageal reflux disease. In: Yamada T, editor. Textbook of Gastroenterology 4th ed. Philadelphia: Lippincott, Williams and Wilkins, 2003: 1196-224
3. Bixquert M. Lo primero es conocer la historia natural. In: Dominguez JE, Sobrino M, editors. Enfermedad por reflujo gastroesofágico. Pautas diagnóstico-terapéuticas para la práctica clínica. Barcelona: Prous Science, 2003: 1-10
4. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999; 44 Suppl 2: S1-S16
5. Dent J, Jones R, Kahrilas P, et al. Management of gastrooesophageal reflux disease in general practice. BMJ 2001; 322: 344-7
6. Galmiche JP, Bruley des Varannes S. Endoscopy-negative reflux disease. Curr Gastroenterol Rep 2001; 3: 206-14
7. Pace F, Bollani S, Molteni P, et al. Natural history of gastroesophageal reflux disease without esophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis 2004; 36: 111-5
8. Kahrilas PJ, Pandolfino JE. Gastroesophageal reflux disease and its complications, including Barrett's metaplasia. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders, 2002: 599-622.
9. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of H. pylori infection - The Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167-80
10. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and H. pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22
11. Freston JW. Should we eradicate H. pylori before long term antireflux therapy? Gut 2001; 49: 616-7
12. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 319-26
13. McColl KEL. H. pylori infection and long term proton pump inhibitor therapy. Gut 2004; 53: 5-7
14. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of H. pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12-20
15. Freston JW. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997; 92 Suppl 5: 1S-7S
16. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005; 19: 15-35
17. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661-4
18. Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. Curr Gastroenterol Rep 2002; 4: 218-24
19. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80
20. Marzo M, Alonso P, Bonfill X, et al. Centro Cochrane Iberomaericano. Clinical practice guideline on the management of patients with gastroesophageal reflux disease (GERD). Gastroenterol Hepatol 2002; 25: 85-110
21. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41
22. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-esophageal reflux disease: double-blind controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J 1999; 318: 502-7
23. Stalhammar N-O, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-esophageal reflux disease. Pharmacoeconomics 1999; 16: 483-7
24. Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastroesophageal reflux disease with omeprazole compared with ranitidine. Results from a multi-center clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19-27
25. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment and complications. Am J Gastronterol 2000; 95: 368-72
26. Lind T, Havelund T, Lundell L, et al. On-demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis - a placebocontrolled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14
27. Talley NJ, Venables TL, Green JRB, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastroesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63
28. Ponce J, Argüello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004; 49: 931-6
29. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA 2001; 285: 2331-8
30. Peterson WL, Kharilas PJ, Berardi RR, et al. Improving the management of GERD: evidence-based therapeutic strategies, in Freston JW (ed), Acid Related Diseases Am Gastroenterol Assoc, Self Study Program 2003; 15-40
31. Carballo F. Tratamiento a largo plazo de la ERGE. Análisis coste-efectividad del tratamiento farmacológico (a demanda y continuo) y el tratamiento quirúrgico. Gastroenterol Hepatol 2001; 24 Suppl 2: 54-60
32. Bammer T, Hinder RA, Klaus A, et al. Five-to-eight year outcome of the first laparoscopic Nissen fundoplications. J Gastrointestinal Surg 2001; 5: 43-8
33. Nilsson G, Wenner J, Larsson S, Jonson F. Randomized clinical trial of laparoscopic versus open fundoplication for gastro-esophageal reflux. Br J Surg 2004; 91: 552-9
34. Johnson DA. Endoscopic therapy for GERD - baking, sewing or stuffing: an evidence-based perspective. Rev Gastroenterol Disord 2003; 3: 142-9
35. Hogan WJ. Endoscopic therapy for gastroesophageal reflux disease. Curr Gastroenterol Rep 2003; 5: 206-12